Skip to main content

Nifty -0.6%: internals confirm a broad decline, not a dip

Net new highs just went negative, decliners beat advancers 1,543 to 941, and the Stage-2 cohort keeps shrinking.

Wednesday, 2 September 20262 min readStage2Stocks Market Desk

Nifty 50
23,914
-0.6% on the day
Market
Neutral — Fading
2 sessions in this state
Breadth
41%
above 200-DMA · narrow
Adv / Dec
941 / 1,543
decliners ahead
52w highs / lows
160 / 166
net -6
Stage-2 share
34%
cohort narrowing

The tape is hollowing out, and today is not a dip inside strength — it is the continuation of a broad decline. Net new highs turned negative for the first time in this sequence, the fast breadth gauge has collapsed from 46% to 36% in six sessions, and the Stage-2 cohort is narrowing. The regime has shifted to transition with a neutral-to-down near-term read, and the internals are not giving any reason to argue otherwise.

Trajectory: deterioration is broad and accelerating

The slow structural gauge — the share of stocks above their 200-day average — has slid from 43% to 40.6% over the past six sessions, confirming this is not a short-term wobble. The fast gauge, stocks above their 20-day average, has dropped sharply from 46.4% to 36.5% in the same window, with decliners beating advancers in four of the last five sessions and today's net new highs printing at minus six — the first negative reading in the series. Over the last five days, 68 stocks moved from Stage 2 into Stage 3 against only 31 moving the other way, a net drain of 37 names from the advancing cohort. Index, breadth and leadership are deteriorating together; the screener's own trajectory classification calls this a broad decline, and the numbers back it.

Leadership: defensive rotation, thin and unconvincing

Today's sector leadership — Utilities up 1%, Energy up 0.5%, Real Estate barely positive — is defensive in character and thin in conviction. Over one and three months, Health Care and Real Estate hold the top spots, which is a narrowing of leadership rather than a broadening. The Stage-2 cohort is expanding fastest in Consumer Staples and Energy, which fits the defensive rotation but is not the broad, cyclical participation that underpins a healthy advance. Bliss GVS Pharma cleared the screen with the highest relative strength rank in the Health Care names, and Asian Energy Services sits at the top of the Energy list — both are what the screen surfaces today, in a market where follow-through rates on new setups are falling as the cohort shrinks.

Leading Stage-2 setups
StockSectorSetup% 1D
Asian Energy Services LtdEnergy9.8+3.2%
Bliss GVS Pharma LtdHealth Care9.8+2.9%
Indo Borax and Chemicals LtdMaterials9.8-1.9%
Raghav Productivity Enhancers LtdMaterials9.8+2.8%
Ratnaveer Precision Engineering LtdIndustrials9.6-1.8%
Marine Electricals (India) LtdIndustrials9.6-0.3%
Omaxe LtdReal Estate9.4+4.7%
Mawana Sugars LtdConsumer Staples9.4+3.9%
Sector performance — cap-weighted, ranked by today’s move
Sector1D1M3MRSStage 2
Utilities+1.0%-5.1%-8.2%5621%
Energy+0.5%+0.7%+1.5%5941%
Real Estate+0.1%+0.8%+14.9%5425%
Materials-0.1%-0.5%+1.0%6536%
Health Care-0.1%+1.6%+12.4%7148%
Communication Services-0.4%-0.3%+7.9%5921%
Financials-0.4%-1.9%+5.6%5934%
Consumer Staples-0.4%-4.2%+0.1%4535%
Industrials-0.7%-0.6%+4.1%6832%
Consumer Discretionary-0.8%-0.4%+11.2%6236%
Information Technology-1.1%-1.2%+5.0%4727%
Share of NSE stocks in Stage 2Mar 2026 – Aug 2026 · weekly
0%10%20%30%40%50%60%70%Jul 26Nifty 50Stocks in Stage 2Latest: 35%
The share of NSE stocks in Stage 2 over the six months to this wrap, with the Nifty's shape above it: the market underneath the day's numbers. Source: Stage2Stocks classification of every NSE stock with enough history, each week.
Try it on Stage2StocksHow to read this chart Lesson 3 of the course: why the Nifty isn't the market, and what the share of stocks in Stage 2 tells you.

Work the same data live: open the full stock screener, watch the live market dashboard, or check the market-timing read. New to the method? Start with the four stages.

Stage2Stocks is an educational stage-analysis screener. These wraps describe what the screen shows across NSE cash equities — they are not investment advice, recommendations, or buy/sell calls. Always do your own research.

All market wraps →